Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasiglucagon during exercise in T1D
NCT04192019Phase 1Withdrawn
- Sponsor
- Insel Gruppe
- Start
- Apr 2023
- Primary completion
- Apr 2024
- Modality
- Peptides, Recombinant Proteins and Enzymes
01
Overview
Phase 1, randomised, open-label trial of dasiglucagon in hypoglycemia (3 arms), sponsored by Insel Gruppe. Primary endpoint: Time to hypoglycaemia at 60 minutes. Planned start Apr 2023; status: withdrawn.
02
Drugs
dasiglucagon
03
Conditions
hypoglycemia
Beyond the preview
Go deeper on NCT04192019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04192019.